These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7416212)

  • 21. Depo-Provera in adolescents: effects of early second injection or prior oral contraception.
    Harel Z; Biro FM; Kollar LM
    J Adolesc Health; 1995 May; 16(5):379-84. PubMed ID: 7662688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
    Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
    Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contraceptive and endometrial effects of medroxyprogesterone acetate.
    Lee RA
    Am J Obstet Gynecol; 1969 May; 104(1):130-3. PubMed ID: 5777697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In utero exposure to steroid contraceptives and outcome of pregnancy.
    Pardthaisong T; Gray RH
    Am J Epidemiol; 1991 Oct; 134(8):795-803. PubMed ID: 1835282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
    Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
    Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Menopause, medroxyprogesterone and breathing during sleep.
    Block AJ; Wynne JW; Boysen PG; Lindsey S; Martin C; Cantor B
    Am J Med; 1981 Mar; 70(3):506-10. PubMed ID: 7211892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depo-Provera highly effective as injectable contraceptive.
    Denniston GC
    Contracept Technol Update; 1985 Dec; 6(12):167-8. PubMed ID: 12280301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term contraception with Depo-Provera: a clinical evaluation.
    Mukherjea M; Mukherjee P; Biswas R
    Int J Fertil; 1980; 25(2):122-6. PubMed ID: 6117526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential use of conjugated estrogens and medroxyprogesterone in the climacteric syndrome: clinical and histological findings.
    Figueroa-Casas PR; Schlaen I
    Maturitas; 1988 Mar; 9(4):309-13. PubMed ID: 2837619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Not FDA-approved, but experts recommend Depo-Provera.
    Contracept Technol Update; 1992 Jan; 13(1):1-7. PubMed ID: 12343458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
    Keder LM; Rulin MC; Gruss J
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in blood lipids and side effects induced by depo-provera in Nigerian women.
    Fajumi JO
    Contraception; 1983 Feb; 27(2):161-75. PubMed ID: 6221882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria.
    Hu E; Ikeako LC; Obiora-Okafor NC
    Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA board investigates Depo-Provera safety.
    Contracept Technol Update; 1983 Mar; 4(3):25-7. PubMed ID: 12266161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
    Gallagher JC; Kable WT; Goldgar D
    Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.
    Hergenroeder AC; Smith EO; Shypailo R; Jones LA; Klish WJ; Ellis K
    Am J Obstet Gynecol; 1997 May; 176(5):1017-25. PubMed ID: 9166162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral medroxyprogesterone in the treatment of postmenopausal symptoms.
    Schiff I; Tulchinsky D; Cramer D; Ryan KJ
    JAMA; 1980 Sep; 244(13):1443-5. PubMed ID: 6775094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.